STOCK TITAN

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

IDEAYA Biosciences (NASDAQ: IDYA) announced that its Compensation Committee granted non-qualified stock options to two newly hired employees on October 31, 2024. The grants, made under the company's 2023 Employment Inducement Incentive Award Plan, total 62,800 shares with an exercise price of $28.15 per share, matching the closing price on Nasdaq that day. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment.

IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato che il suo Comitato di Compensazione ha concesso opzioni su azioni non qualificate a due nuovi dipendenti assunti il 31 ottobre 2024. Le concessioni, effettuate nell'ambito del piano di incentivi per l'assunzione del 2023, ammontano a un totale di 62.800 azioni con un prezzo di esercizio di $28,15 per azione, corrispondente al prezzo di chiusura su Nasdaq di quel giorno. Le opzioni hanno una durata di 10 anni e si matureranno in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi tre anni, a condizione di continuare l'impiego.

IDEAYA Biosciences (NASDAQ: IDYA) anunció que su Comité de Compensación otorgó opciones sobre acciones no calificadas a dos nuevos empleados contratados el 31 de octubre de 2024. Las concesiones, realizadas bajo el Plan de Incentivos por Empleo de 2023 de la compañía, totalizan 62,800 acciones con un precio de ejercicio de $28.15 por acción, igualando el precio de cierre en Nasdaq ese día. Las opciones tienen un plazo de 10 años y se irán adquiriendo durante cuatro años, con el 25% adquiriéndose después de un año y el 75% restante mensual durante tres años, condicionado a la permanencia en el empleo.

IDEAYA Biosciences (NASDAQ: IDYA)는 2024년 10월 31일에 두 명의 새로 고용된 직원에게 비정규 주식 옵션을 부여했다고 발표했습니다. 이 부여는 회사의 2023년도 고용 유인 인센티브 보상 계획에 따라 이루어졌으며, 총 62,800주에 해당하고 주당 행사가는 $28.15로, 이날 Nasdaq의 종가와 일치합니다. 옵션의 유효 기간은 10년이며, 4년에 걸쳐 분배됩니다. 1년 후 25%가 발생하고, 나머지 75%는 3년에 걸쳐 매월 발생하며, 고용 유지에 따라 조건이 달라집니다.

IDEAYA Biosciences (NASDAQ: IDYA) a annoncé que son Comité de Compensation a accordé des options d'actions non qualifiées à deux nouveaux employés embauchés le 31 octobre 2024. Les attributions, effectuées dans le cadre du Plan d'Incitation à l'Emploi 2023 de la société, totalisent 62 800 actions avec un prix d'exercice de $28,15 par action, correspondant au prix de clôture sur Nasdaq ce jour-là. Les options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25% acquis après un an et les 75% restants acquis mensuellement sur trois ans, sous réserve de maintien dans l'emploi.

IDEAYA Biosciences (NASDAQ: IDYA) gab bekannt, dass der Vergütungsausschuss Nicht-qualified Stock Options an zwei neu eingestellte Mitarbeiter am 31. Oktober 2024 gewährt hat. Die Gewährungen, die im Rahmen des Unternehmensplans für Anreizvergaben 2023 vorgenommen wurden, belaufen sich auf insgesamt 62.800 Aktien mit einem Ausübungspreis von $28,15 pro Aktie, was dem Schlusskurs an der Nasdaq an diesem Tag entspricht. Die Optionen haben eine Laufzeit von 10 Jahren und werden über einen Zeitraum von vier Jahren vesten, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über drei Jahre vesten, sofern die Anstellung fortgesetzt wird.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 31, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $28.15 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302293866.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is the exercise price of IDYA's newly granted stock options on October 31, 2024?

The stock options were granted with an exercise price of $28.15 per share, equal to IDEAYA's closing price on The Nasdaq Global Select Market on the date of grant.

How many shares were granted in IDYA's inducement grants on October 31, 2024?

IDEAYA Biosciences granted non-qualified stock options to purchase an aggregate of 62,800 shares of common stock to two newly hired employees.

What is the vesting schedule for IDYA's October 31, 2024 stock option grants?

The stock options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years.

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

IDYA Rankings

IDYA Latest News

IDYA Stock Data

2.24B
85.54M
1.04%
110.9%
10.78%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO